BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York

TEL AVIV, Israel, August 30, 2018 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, will present a company update at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 4-6, 2018 at the St. Regis Hotel in New York City.

The BioLineRx presentation is scheduled to start at 9:35 a.m. EDT on Wednesday, September 5, 2018. A live audio webcast of the presentation will be available online on the Investor Page of the Company's website. An archive of the event will also be available for those unable to listen live.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (http://www.rodmanevents.com) to register for the conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

About BioLineRx 

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a multi-therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and has initiated a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which has recently initiated a Phase 1/2a study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (known as Merck in the US and Canada), on the basis of which the Company is conducting a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA^®; and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications and AML.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Contact:

PCG Advisory
Vivian Cervantes

Investor Relations

+1-646-863-6274
[email protected]


or

Tsipi Haitovsky

Public Relations

+972-52-598-9892
[email protected]

SOURCE BioLineRx Ltd.